Janux Therapeutics, Inc. (JANX)
Market Cap | 1.96B |
Revenue (ttm) | 8.08M |
Net Income (ttm) | -58.29M |
Shares Out | 51.66M |
EPS (ttm) | -1.32 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 250,244 |
Open | 38.35 |
Previous Close | 37.92 |
Day's Range | 36.94 - 39.23 |
52-Week Range | 5.65 - 58.69 |
Beta | 4.30 |
Analysts | Strong Buy |
Price Target | 56.17 (+49.03%) |
Earnings Date | Mar 8, 2024 |
About JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth ... [Read more]
Financial Performance
In 2023, JANX's revenue was $8.08 million, a decrease of -6.14% compared to the previous year's $8.61 million. Losses were -$58.29 million, -7.56% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price forecast is $56.17, which is an increase of 49.03% from the latest price.
News
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)
Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights.
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants.
Janux Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering of Common Stock.
Janux Therapeutics surges as trial data for prostate cancer therapy shows promise
Janux Therapeutics shares more than doubled in value before the bell on Tuesday after the drug developer reported encouraging interim early-stage data for its experimental therapy to treat an advanced...
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
SAN DIEGO--(BUSINESS WIRE)---- $JANX--PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors.
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008.
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer.
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights.
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights.
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants.
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs.
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
SAN DIEGO--(BUSINESS WIRE)---- $JANX #CD28--Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development.
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences.
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlight
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc.
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...
Janux Therapeutics to Present at Upcoming Investor Conferences in November
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary tech...
Janux Therapeutics Appoints Winston Kung to Board of Directors
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary tech...
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September